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CELL LINES HAVING ENHANCED CELL 
LONGEVITY AND PROTEIN EXPRESSION 
RELATED APPLICATIONS 
This application is a Continuation of US. application Ser. 
No. 11/016,871, ?led on Dec. 21, 2004, Which issued as US. 
Pat. No. 7,629,160, the disclosure of Which Application is 
incorporated by reference herein. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates to the ?elds of nucleic acid con 
structs and cell lines that alloW for the increased expression of 
endogenous or heterologous target protein. 
2. Background 
The immediate challenge created by the genomics era is 
the production of the novel proteins to understand their func 
tion. Current methods of expressing genes in a mammalian 
cell include the use of viral vectors, such as those Which are 
derived from retroviruses, adenoviruses, herpes viruses, vac 
cinia viruses, polio viruses, sindbis viruses, or adeno-associ 
ated viruses. Other methods of expressing an exogenous gene 
in a mammalian cell include direct injection of DNA, the use 
of ligand-DNA conjugates, the use of adenovirus-ligand 
DNA conjugates, calcium phosphate precipitation, and meth 
ods Which utiliZe a liposome- or polycation-DNA complex. 
Due to its advantages in versatility and speed, the Bacu 
lovirus Expression Vector System (BEVS) used in conjunc 
tion With insect cells has become Well-established for the 
production of proteins, particularly recombinant glycopro 
teins. Baculovirus mediated protein expression provides cor 
rect folding of recombinant protein as Well as disul?de bond 
formation, oligomeriZation and other important post-transla 
tional modi?cations that impart proper biological activity and 
function. With regard to protein folding and po st-translational 
processing, insect cells are second only to mammalian cell 
lines When expressing a eukaryotic protein, for example. The 
frequent use of baculovirus arises from the relative ease and 
speed With Which a heterologous protein can be expressed on 
the laboratory scale and the high chance of obtaining a bio 
logically active protein. Insect cells can be groWn on serum 
free media Which is an advantage in terms of costs as Well as 
of biosafety. For large scale culture, conditions have been 
developed Which meet the special requirements of insect 
cells. 
In nature, baculoviruses are double-stranded DNA-con 
taining viruses that infect a variety of different insect species. 
The nuclear polyhedrosis viruses, Which comprise subgroup 
A of the Family Baculoviridae, induce the formation of 
paracrystalline occlusion bodies in the nuclei of infected host 
cells. These occlusion bodies are composed primarily of a 
single viral protein Which is expressed at very high levels 
(polyhedrin). In later stages of the infection cycle, polyhedrin 
may account for more than 50% of the total protein in an 
infected cell. The polyhedrin gene has been cloned and 
sequenced and its unique features have provided the basis for 
the development of a series of baculovirus expression vectors 
(BEVs: Summers, M. D. and Smith, G. E., TAES Bull. 1555 
(1987); LuckoW, V. A. and Summers, M. D., Biotechnology 
6:47-55 (1988); Miller, L. K., Ann. Rev. Microbiol. 42:177 
179 (1988); US. Pat. No. 4,745,051, G. E. Smith and M. D. 
Summers (Filed May 27, 1983; Issued May 17, 1988)). 
BEVs are recombinant baculoviruses in Which the coding 
sequence for polyhedrin has been replaced With the coding 
sequence for a desired protein. In general, this approach 
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involves the construction and isolation of recombinant bacu 
loviruses in Which the coding sequence for the chosen gene 
has been inserted behind the promoter for the nonessential 
polyhedrin viral gene (Pennica, et al, Mol. Cell. Biol. 4:399 
406 (1984); Smith, et al, L. V1rol. 46:584-593 (1983); Smith, 
G. E. and M. D. Summers, Mol. Cell. Biol. 3:2156-2165 
(1983). Several advantages may exist When employing the 
BEV system. One of these advantages is the strong polyhe 
drin promoter Which directs a high level of expression of the 
inserted heterologous nucleic acid encoding the target 
polypeptide. The neWly expressed heterologous target pro 
tein accumulates in large amounts Within these infected insect 
cells. Thus, as a result of the relative strength of the polyhe 
drin promoter, many different gene inserts canbe expressed at 
very high levels. 
In addition to providing a high expression level, another 
advantage of the BEV system is the ease With Which these 
baculoviruses are produced and identi?ed. This process 
begins by co-transfecting Wild-type viral DNA and a “transfer 
vector” into susceptible host cells. A transfer vector is de?ned 
as a bacterial plasmid Which contains a desired gene directly 
3' to the polyhedrin promoter, as Well as long viral sequences 
?anking the promoter on the 5' side. During cotransfection, 
homologous recombination occurring betWeen viral and 
transfer vector DNA Will produce a small percentage of viral 
genomes in Which the polyhedrin gene has been replaced by 
the desired heterologous nucleic acid encoding the target 
polypeptide (0.1-5.0%). The Wild-type progeny can be differ 
entiated from the recombinant progeny by a conventional 
viral plaque assay. Recombinants in Which the polyhedrin 
gene has been replaced, can be identi?ed by their occlusion 
negative plaque phenotype observed in a background of 
occlusion-positive Wild-type plaques. 
Because the polyhedrin gene is a non-essential gene for 
productive viral infection, another advantage of baculovirus 
expression vectors is that the recombinants are viable, helper 
independent viruses. Also, baculoviruses only infect Lepi 
dopteran insects; thus, they are noninfectious for vertebrates, 
and are, therefore, relatively safe genetic manipulation 
agents. 
Notwithstanding the successes of BEVS and other systems 
for expression of heterologous proteins in insect and mam 
malian cell culture, maintenance of the viability of trans 
formed or transfected cell cultures remains a capricious 
undertaking. Many laboratories refer to tissue culture as a 
“black art,” due to the numerous variables that make it di?i 
cult to determine solutions When problems arise. An intensive 
and time-consuming systematic approach that examines the 
symptoms and meticulously retraces each step in the culture 
process is usually required to identify the material or critical 
procedure that has created the viability issue. Problems such 
as poor cell groWth and abnormal morphology can result from 
materials that are poor quality, inappropriate, compromised, 
or contaminated and/ or equipment that must be re-calibrated 
or re-setup to comply With manufacturer usage. Perhaps most 
frustrating, cells of different lots may react differently to 
standardiZed media and serum supplements resulting in unex 
pected toxicity or nutritional de?ciency. Therefore, much of 
the time and expense invested in preparation of protein 
expression vectors may be lost When a protein production 
facility experiences dif?culty in optimiZing cell culture pro 
tein production conditions. As such it Would be of great 
economic bene?t to provide a generaliZed agent to a cell line 
to increase its viability, longevity and protein production 
capacity. 
Insects, like other animals, have effective immune systems 
to combat both biotic and abiotic foreign invasion. Interest 
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ingly, endoparasitic insects spend a part of their life cycle 
inside the body of other insect hosts. Considerable effort has 
been expended investigating the mechanism by Which these 
endoparasitic insects avoid the host immune system in this 
parasitic relationship. 
One Well characterized parasitoid-host system in Which 
there is immune system evasion is that of the endoparasitic 
Wasp Campolelis sonorensis and its host, the tobacco bud 
Worm Heliolhis virescens. In investigating hoW immunosup 
pression is regulated in this system, it became apparent that a 
group of Wasp viruses, knoWn generically as polydnaviruses 
(PDVs), play a role in the suppression of the host immune 
system. Bracoviruses (BVs) and ichnoviruses (IVs) are the 
tWo main parasitic Wasp associated PDVs. It is knoWn that 
during oviposition, the endoparasitic insect, for example C. 
sonorensis, injects not only eggs but also polydnavirus and 
oviduct proteins. Shortly thereafter, the host insect immune 
system begins to shoW evidence of altered activity and the 
endoparasitoid eggs remain free from encapsulation. The pre 
cise mechanism of this immune suppression is not presently 
understood. 
The WHv1.0, WHv1.6 andVHv1.1 genes of C. sonorensis 
polydnavirus (CsPDV) have been cloned and sequenced. 
These genes are described as members of a polydnavirus 
“cysteine-rich” gene family. (Dib-Hajj et al., Proc. Natl. 
Acad. Sci. (USA) 90: 3765 (1993)). It has been conjectured 
that these genes may play a role in preventing the recognition 
of foreign objects and/or the normal response of components 
of the immune system. (Summers et al., Proc. Natl.Acad. Sci. 
(USA) 92: 29 (1995)). Indeed, the VHv1.1 gene product of 
the C. sonorensis polydnavirus has been implicated in the 
inhibition of the cellular immune response. This 30 kDa pro 
tein is shoWn by indirect immuno?uorescence to bind both 
granulocytes and plasmatocytes and is thought to inhibit 
encapsulation. (Li et al., J. Virol., 68: 7482 (1994)). 
Recent PDV genome sequencing projects have revealed a 
novel family of closely related genes that exist in several 
genomes including, but not limited to, the C. sonorensis IV 
(CsIV) Hyposolerfugilivus IV (HfIV), Glyplafumlferana IV 
(GfIV), Microplilis demolilor BV (MdBV), Colesia congre 
gala BV (CcBV), Glyplapanleles indiensis BV (GiBV), and 
Toxoneuron nigriceps BV (TnBV) genomes. This family of 
genes has been named vankyrins as their open reading frames 
(ORFs) encode proteins almost exclusively made up of 
ankyrin repeat domains. The PDV ankyrin repeat-carrying 
proteins shoW signi?cant identity to the ankyrin repeats of the 
IKB family of transcription factor inhibitors suggesting that 
they disrupt intracellular NF-KB mediated signal transduction 
cascades knoWn to play a role in both vertebrate and inverte 
brate immune responses. There are seven vankyrin ORFs 
encoded by the CsIV genome. 
The inventors have discovered that the expression of tWo 
CsIV vankyrins from a heterologous expression vector sys 
tem increases the vitality, longevity, and therefore the protein 
productive capacity of cells in culture. 
All references cited herein are hereby incorporated by ref 
erence in their entirety for all purposes. 
SUMMARY OF THE INVENTION 
One aspect of the invention relates to a vankyrin expression 
vector comprising a nucleic acid encoding the polypeptide of 
SEQ ID NO: 2. Another aspect of the invention relates to a 
vankyrin expression vector comprising a nucleic acid encod 
ing the polypeptide of SEQ ID NO: 4. Yet another aspect of 
the invention relates to a vankyrin expression vector compris 
ing a nucleic acid that hybridiZes to the nucleic acid of SEQ 
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ID NO: 1 under stringent conditions Wherein the nucleic acid 
encodes a polypeptide capable of enhancing longevity and/or 
protein production of a cell line in Which it is expressed. A 
further aspect of the invention relates to a vankyrin expression 
vector comprising a nucleic acid that hybridiZes to the nucleic 
acid of SEQ ID NO: 3 under stringent conditions Wherein the 
nucleic acid encodes a polypeptide capable of enhancing 
longevity and/ or protein production of a cell line in Which it is 
expressed. Another aspect of the invention relates to a 
vankyrin expression vector comprising a nucleic acid of SEQ 
ID NO: 1.Yet another aspect relates to a vankyrin expression 
vector comprising a nucleic acid of SEQ ID NO: 3. 
Another aspect of the invention relates to a recombinant 
cell comprising a ?rst nucleic acid selected from the group 
consisting of a nucleic acid encoding the polypeptide of SEQ 
ID NO: 2 a nucleic acid that hybridiZes to the nucleic acid of 
SEQ ID NO: 1 under stringent conditions Wherein the nucleic 
acid encodes a polypeptide capable of enhancing longevity 
and/or protein production of a cell line in Which it is 
expressed; and a nucleic acid of SEQ ID NO: 1; and/or a 
second nucleic acid selected from the group consisting of: a 
nucleic acid encoding the polypeptide of SEQ ID NO: 4; a 
nucleic acidthat hybridiZes to the nucleic acid of SEQ ID NO: 
3 under stringent conditions Wherein the nucleic acid encodes 
a polypeptide capable of enhancing longevity and/ or protein 
production of a cell line in Which it is expressed; and a nucleic 
acid of SEQ ID NO: 3. 
Another aspect of the invention relates to a method of 
enhancing target protein production of a cell line producing a 
target protein comprising transforming cells of the cell line 
With a vankyrin expression vector, groWing the cell line; and 
isolating the target protein from the cell line. 
Another aspect of the invention relates to a method of 
generating a recombinant cell line capable of enhanced target 
protein production comprising transforming a cell line With a 
heterologous nucleic acid encoding and driving the expres 
sion of a target protein; and transforming cells of the cell line 
With a vankyrin expression. 
Yet another aspect of the invention relates to a method of 
generating a recombinant target protein-producing cell line 
capable of enhanced target protein production comprising 
constructing a vankyrin expression vector and transforming 
cells of the cell line With the vankyrin expression vector. 
Another aspect of the invention relates to a method of 
enhancing longevity of a cell line producing a target protein 
comprising transforming cells of the cell line With a vankyrin 
expression vector, to obtain a transformed cell line producing 
a target protein; groWing the transformed cell line producing 
a target protein longer than a the cell line not transformed With 
the vector. 
Additional advantages of the present invention Will 
become readily apparent to those skilled in this art from the 
folloWing detailed description, Wherein only the preferred 
embodiment of the invention is shoWn and described, simply 
by Way of illustration of the best mode contemplated of car 
rying out the invention. As Will be realiZed, the invention is 
capable of other and different embodiments, and its several 
details are capable of modi?cations in various obvious 
respects, all Without departing from the invention. The 
present invention may be practiced Without some or all of 
these speci?c details. In other instances, Well knoWn process 
operations have not been described in detail, in order not to 
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unnecessarily obscure the present invention. Accordingly, the 
drawings and description are to be regarded as illustrative in 
nature, and not as restrictive. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Morphology of 4-day post infected (4 d p.i.) Sf9 
(panel A) and Sl-2 (panel B) cells exposed to recombinant 
AcMNPV’s expressing CsIV vankyrin proteins. Cells 
infected With recombinant viruses expressing fat body spe 
ci?c P-ank-l and I2-ank-3 proteins (asterisks) are more stable 
and resemble non-infected cells at 4 d p.i. Cells exposed to 
recombinant viruses expressing the remaining CsIV genes 
undergo apoptosis and lysis by 4 d pi. and resemble cells 
infected With Wild type AcMNPV. 40>< magni?cation. 
FIG. 2. Protein expression is extended in Sf9 cells infected 
With recombinant AcMNPV expressing Fat-Body speci?c 
CsIV ankyrin genes P-ank-l and I2-ank-3. Western blots rep 
resent detection of proteins in freshly overlayed culture media 
presented to cells at each subsequent day folloWing infection. 
The CsIV vankyrin genes are intracellular proteins and lack 
secretory signals, thus protein detected in the media overlay is 
the result of that released by cell lysis or rupture folloWing 
infection. Delayed detection of proteins from P-ank-l and 
I2-ank-3 viruses until day 3 pi. is resultant of the enhanced 
longevity of Sf9 cells occurring early during infection by 
these viruses (as evidenced in FIG. 1). 
FIG. 3. The cDNA and amino acid sequences of P-ank-l 
(SEQ ID NO: 1 and 3, respectively) and I2-ank-3 (SEQ ID 
NO: 2 and 4, respectively). 
FIG. 4. Morphology of Sf9 cells exposed to recombinant 
AcMNPV’s expressing CsIV vankyrin proteins over time. 
Cells infected With recombinant viruses expressing fat body 
speci?c P-ank-l and I2-ank-3 proteins (asterisks) are more 
stable and increase the longevity of the cells through 6 days 
(6D) post infection such that they resemble non-transfected 
control cells. Cells exposed to recombinant viruses express 
ing the remaining CsIV genes undergo apoptosis and lysis by 
4 d pi. and resemble cells infected With Wild type AcMNPV. 
40>< magni?cation. 
FIG. 5. Morphology of Sl-2 cells exposed to recombinant 
AcMNPV’s expressing CsIV vankyrin proteins over time. 
Cells infected With recombinant viruses expressing fat body 
speci?c P-ank-l and I2-ank-3 proteins (asterisks) are more 
stable and maintain the vitality of the cells through 6 days 
(6D) post infection such that they resemble non-transfected 
control cells. Cells exposed to recombinant viruses express 
ing the remaining CsIV genes undergo apoptosis and lysis by 
4 d pi. and resemble cells infected With Wild type AcMNPV. 
40>< magni?cation. 
FIG. 6. ShoWs the yield of recombinant vankyrin protein 
produced in cells infected by different recombinant AcMN 
PVs. A cell line Was infected With different recombinant 
AcMNPVs encoding different vankyrin proteins. Next, the 
vankyrin protein encoded by the each differing recombinant 
AcMNPV Was isolated and quanti?ed. The inventors note 
that cells infected by recombinant AcMNPVs encoding 
P-ank-l and I2-ank-3 produced signi?cantly larger quantities 
of their encoded CsIV vankyrin proteins, i.e., P-ank-l and 
I2-ank-3 protein, respectively, than cells transgenically 
expressing the other CsIV vankyrin proteins. 
DETAILED DESCRIPTION OF THE INVENTION 
It is an object of the current invention to provide methods 
and compositions relating to the expression of vankyrin pro 
teins in cell lines to increase their viability, longevity and 
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capacity for protein production. The vankyrin gene family 
comprises 7 genes on CsIV genome segments P and I2. Each 
vankyrin gene encodes an open reading frame of about 500 
bp possessing 4 ankyrin repeat protein motifs. The vankyrin 
protein motifs shoW signi?cant identities to ankyrin motifs of 
Cactus, the Drosophila IKB protein. MdBV and CsIV 
vankyrin genes align With the 4 C-terminal ankyrin repeat 
domains of IKBS but lack N-terminal repeats that function to 
mask nuclear localiZation signals (NLS) and sequester unin 
duced NF-KB dimers in the cytoplasm. 
The seven vankyrin genes are I2-ank-l, I2-ank-2, I2-ank-3, 
P-ank-l, P-ank-2, P-ank-3 and P-ank-4. The inventors have 
discovered that the expression of P-ank-l and I2-ank-3 pro 
teins in cell culture has increased the cells’ viability, longevity 
and, therefore, capacity for endogenous and/ or heterologous 
target protein production. Speci?cally, the present invention 
relates to the enhanced expression of endogenous and/or het 
erologous target proteins/polypeptides in recombinant cells 
that are also expressing P-ank-l and/ or I2-ank-3 protein com 
pared to expression host cells that are not expressing P-ank-l 
and/or I2-ank-3 protein. 
Before describing the invention in greater detail the fol 
loWing de?nitions are set forth to illustrate and de?ne the 
meaning and scope of the terms used to describe the invention 
herein: 
The term “nucleic acid molecule” is meant to include 
DNA, RNA and mixed DNA-RNA sequences. In addition to 
the typically found A, T, U, G and C residues, a nucleic acid 
molecule may also include related residues such as, for 
example, inosine (I). 
The term “polynucleotide” or “oligonucleotide” as used 
herein refers to a polymeric form of nucleotides of any length, 
either ribonucleotides or deoxyribonucleotides. This term 
refers only to the primary structure of the molecule. Thus, this 
term includes double and single stranded DNA, triplex DNA, 
as Well as double and single stranded RNA. It also includes 
modi?ed, for example, by methylation and/ or by capping, and 
unmodi?ed forms of the polynucleotide. 
The term “promoter region” refers to a DNA sequence that 
functions to control the transcription of one or more nucleic 
acid sequences, located upstream With respect to the direction 
of transcription of the transcription initiation site of the gene, 
and is structurally identi?ed by the presence of a binding site 
for DNA-dependent RNA polymerase, transcription initia 
tion sites and any other DNA sequences, including, but not 
limited to transcription factor binding sites, repressor and 
activator protein binding sites, calcium or cAMP responsive 
sites, and any other nucleotide sequences knoWn to act 
directly or indirectly to regulate transcription from the pro 
moter. 
The term “heterologous DNA” or “heterologous RNA” 
refers to DNA or RNA that does not occur naturally as part of 
the genome or DNA or RNA sequence in Which it is present, 
or in Which it is found, a cell or location or locations in the 
genome or DNA or RNA sequence that differs from that 
Which it is in found in nature. Heterologous DNA or RNA is 
not endogenous to the cell into Which it is introduced, but has 
been obtained from another cell or synthetically or recombi 
nantly produced. Generally, though not necessarily, such 
DNA encodes RNA and protein not normally produced by the 
cell in Which the DNA is transcribed or expressed. Similarly 
exogenous RNA encodes protein not normally expressed in 
the cell in Which the exogenous RNA is present. Heterologous 
DNA or RNA may also be referred to as foreign DNA or 
RNA. Any DNA or RNA that one of skill in the art Would 
recogniZe as heterologous or foreign to the cell in Which it is 
expressed is herein encompassed by the term heterologous 
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DNA or heterologous RNA. Examples of heterologous DNA 
include, but are not limited to, DNA that encodes a protein, 
polypeptide, reporter nucleic acid sequence, transcriptional 
or translational regulatory sequences, selectable or traceable 
marker protein, such as a protein that confers drug resistance, 
RNA including mRNA and antisense RNA, and ribozymes. 
The term “recombinant polynucleotide” as used herein 
refers to a polynucleotide of genomic, cDNA, semisynthetic 
or synthetic origin Which, by virtue of its origin or manipu 
lation: (1) is not associated With all or a portion of the poly 
nucleotide With Which it is associated in nature and/or (2) is 
linked to a polynucleotide other than that to Which it is linked 
in nature. The term “cDNA” or “complementary DNA” refers 
to single stranded or double stranded DNA sequences 
obtained by reverse transcription of messenger RNA isolated 
from a donor cell. For example, treatment of messenger RNA 
With a reverse transcriptase such as AMV reverse tran 
scriptase or M-MuLV reverse transcriptase in the presence of 
an oligonucleotide primer Will furnish an RNA-DNA duplex 
Which can be treated With RNase H, DNA polymerase and 
DNA ligase to generate double stranded cDNA. If desired, the 
double stranded cDNA can be denatured by conventional 
techniques such as shearing to generate single stranded 
cDNA. 
The term “operably linked” refers to the linkage of a DNA 
segment to another DNA segment in such a Way as to alloW 
the segments to function in their intended manners. A DNA 
sequence encoding a gene product is operably linked to a 
regulatory sequence When it is ligated to the regulatory 
sequence, such as, for example, promoters, enhancers and/or 
silencers, in a manner Which alloWs modulation of transcrip 
tion of the DNA sequence, directly or indirectly. For example, 
a DNA sequence is operably linked to a promoter When it is 
ligated to the promoter doWnstream With respect to the tran 
scription initiation site of the promoter, in the correct reading 
frame With respect to the transcription initiation site, and 
alloWs transcription elongation to proceed through the DNA 
sequence. An enhancer or silencer is operably linked to a 
DNA sequence coding for a gene product When it is ligated to 
the DNA sequence in such a manner as to increase or 
decrease, respectively, the transcription of the DNA 
sequence. Enhancers and silencers may be located upstream, 
doWnstream or embedded Within the coding regions of the 
DNA sequence. A DNA for a signal sequence is operably 
linked to DNA coding for a polypeptide if the signal sequence 
is expressed as a preprotein that participates in the secretion 
of the polypeptide. Linkage of DNA sequences to regulatory 
sequences is typically accomplished by ligation at suitable 
restriction sites or via adapters or linkers inserted in the 
sequence using restriction endonucleases knoWn to one of 
skill in the art. 
The term “target” protein or polypeptide, refers to a protein 
of interest that is expressed in the recombinant cells also 
expressing P-ank-1 and/or l2-ank-3 protein. Preferably, the 
recombinant cell is used as bioreactor for the production of 
the target protein. The target protein may be an endogenous 
protein naturally produced by the ho st cell type. For example, 
if the host cell type is a hybridoma, the target protein may be 
a monoclonal antibody. Alternatively, the target protein can 
be encoded by a heterologous recombinant nucleic acid, eg 
a cDNA. In this case, the target protein Will be a heterologous 
protein, i.e., one that is not naturally expressed by the host cell 
line. 
Central to the invention is the “vankyrin expression vec 
tor.” A vankyrin expression vector is any genetic element, 
e.g., a plasmid, chromosome, virus, capable of bringing about 
the expression of a P-ank-1 (SEQ ID NO: 2) and/or l2-ank-3 
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(SEQ NO: 4) proteins or proteins substantially similar 
thereto, i.e., those having similar amino acid sequences and 
the same functionalities With regard to the ability to provide 
enhanced cell longevity and/or protein productive capacity. 
Preferably, proteins P-ank-1 (SEQ ID NO: 2) and l2-ank-3 
(SEQ NO: 4) are encoded by SEQ ID NO: 1 and SEQ NO: 3, 
respectively. The skilled artisan Will also appreciate that 
invention also encompasses vankyrin expression vector 
sequences comprising sequences substantially identical to 
SEQ ID NOs: 1 and 3. Such sequences may differ from SEQ 
ID NOs: 1 and 3, respectively, With regard to the identity of at 
least one nucleotide base. 
HoWever, all polynucleotides sequences “substantially 
identical” to SEQ ID NOs: 1 and 3 hybridize under stringent 
conditions (as de?ned herein) to all or a portion of the 
complements of SEQ ID NOs: 1 and3 (i.e., target sequences), 
respectively. The terms “hybridize(s) speci?cally” or “spe 
ci?cally hybridize(s)” refer to complementary hybridization 
betWeen an oligonucleotide (e. g., a primer or labeled probe) 
and a target sequence. The term speci?cally embraces minor 
mismatches that can be accommodated by reducing the strin 
gency of the hybridization media to achieve the desired prim 
ing for the PCR polymerases or detection of hybridization 
signal. 
Under stringent hybridization conditions, only highly 
complementary, i.e., substantially identical nucleic acid 
sequences, hybridize. Preferably, such conditions prevent 
hybridization of nucleic acids having 3 or more mismatches 
out of 20 contiguous nucleotides, more preferably 2 or more 
mismatches out of 20 contiguous nucleotides, most prefer 
ably one or more mismatch out of 20 contiguous nucleotides. 
The hybridizing portion of the hybridizing nucleic acid is at 
least about 90%, preferably at least about 95%, or most pref 
erably about at least about 98%, identical to the sequence of 
a target sequence, or its complement. 
Hybridization of a nucleic acid to a nucleic acid sample 
under stringent conditions is de?ned beloW. Nucleic acid 
duplex or hybrid stability is expressed as a melting tempera 
ture (Tm), Which is the temperature at Which the probe disso 
ciates from the target DNA. This melting temperature is used 
to de?ne the required stringency conditions. If sequences are 
to be identi?ed that are substantially identical to the probe, 
rather than identical, then it is useful to ?rst establish the 
loWest temperature at Which only homologous hybridization 
occurs With a particular concentration of salt (eg SSC or 
SSPE). Then assuming that 1% mismatching results in a 1° C. 
decrease in Tm, the temperature of the ?nal Wash in the 
hybridization reaction is reduced accordingly (for example, if 
sequences having >95% identity With the probe are sought, 
the ?nal Wash temperature is decrease by 5° C.). In practice, 
the change in Tm can be betWeen 0.5° C. and 1.5° C. per 1% 
mismatch. 
Stringent conditions involve hybridizing at 68° C. in 
5><SSC/5><Denhart’s solution/1.0% SDS, and Washing in 
0.2><SSC/0.1% SDS at room temperature. Moderately strin 
gent conditions include Washing in 3><SSC at 42° C. Addi 
tional guidance regarding such conditions is readily available 
in the art, for example, Sambrook, Fischer and Maniatis, 
Molecular Cloning, a laboratory manual, (2nd ed.), Cold 
Spring Harbor Laboratory Press, NeW York, (1989) and F. M. 
Ausubel et al eds., Current Protocols in Molecular Biology, 
John Wiley and Sons (1994). 
Moreover, vankyrin expression vector containing poly 
nucleotides “substantially similar or identical” to SEQ ID 
NO: 1 and 3, respectively, are capable of providing a cell line 
With enhanced longevity and/or protein production capabil 
ity. In one embodiment, When expressed in Sf9 or S1-2 cells, 
US 7,842,493 B2 
polynucleotides “substantially similar or identical” to SEQ 
ID NO: 1 and 3, respectively, are capable of improving the 
longevity of those cells to such an extent that they resemble 
non-transfected Sf9 or S1-2 cells, Whereas Sf9 or S1-2 cells 
transfected With a vector not containing polynucleotides 
“substantially similar or identical” to SEQ ID NO: 1 and 3, 
respectively. Preferably, the vector is a baculovirus vector. In 
another embodiment, polynucleotides “substantially similar 
or identical” to SEQ ID NO: 1 and 3, respectively, are capable 
of providing enhanced protein production in a cell line in 
Which they are expressed, relative to a host cell line trans 
fected in a similar manner by a vector lacking suchpolynucle 
otides. For example, polynucleotides “substantially similar or 
identical” to SEQ ID NO: 1 and 3, respectively, When 
expressed in Sf9 or S1-2 cells, are capable providing 
enhanced protein production in those cells, relative to Sf9 or 
S1 -2 cells transfected With a vector not containing polynucle 
otides “substantially similar or identical” to SEQ ID NO: 1 
and 3, respectively. 
The vankyrin expression vector contains sequences to 
facilitate expression of P-ank-1 and/or I2-ank-3 proteins in 
the host cell. Such sequences differ depending on the host 
organism; they include promoter sequences, for example but 
not limited to a polyhedrin promoter, SV40 promoter, or a 
conditionally activated promoter such as a metallothionein 
promoter to effect transcription; enhancer sequences to 
increase transcription; ribosomal binding site sequences; and 
transcription and translation termination sequences. The vec 
tor may also optionally behave either as an autonomous unit 
of polynucleotide replication Within a cell (i.e., capable of 
replication under its oWn control) or being rendered capable 
of replication by insertion into a host cell chromosome, hav 
ing attached to it another polynucleotide segment, so as to 
bring about the replication. Suitable vectors include, but are 
not limited to, viruses, plasmids, bacteriophages, yeast arti 
?cial chromosomes (YACs), cosmids, and the like. Vectors 
may contain polynucleotide sequences Which are necessary 
to effect ligation or insertion of the vector into a desired host 
cell and the expression of its coding region(s). Additionally, 
the vankyrin expression vector itself may also contain heter 
ologous nucleic acids encoding and driving the expression of 
target heterologous proteins and/or reporter proteins. 
The skilled artisan Will recogniZe that a Wide range of 
vectors may be constructed to permanently, constitutively, 
conditionally or transiently drive P-ank-1 and/or I2-ank-3 
expression in a Wide range of insect and mammalian cell 
lines. The skilled artisan Would knoW hoW to operably link the 
aforementioned sequences. It is to be understood that this 
invention is intended to include other forms of expression 
vectors, host cells and transformation techniques Which serve 
equivalent functions and Which become knoWn to the art 
hereto. 
The preferred “vankyrin expression vector” is part of a 
baculovirus expression system engineered to express P-ank-1 
and/ or I2-ank-3 proteins and the control of a polyhedrin pro 
moter in the cells it infects. Most, preferably, the baculovirus 
is an Aulographa californica baculovirus (AcNPV), and 
expression of P-ank-1 and/or I2-ank-3 protein is driven by a 
polyhedrin promoter. The baculovirus Aulographa califor 
nica mono nuclear polyhedrosis virus (AcMNPV), used in 
the examples as the original source of viral DNA Was isolated 
according to procedures described in G. E. Smith and M. D. 
Summers, Virology, 89:517-527 (1978) and G. E. Smith and 
M. D. Summers, J. Virol., 39:125-137 (1981). According to 
the preferred embodiment of this invention, a particular strain 
of AcMNPV, E2, is utiliZed. HoWever, those skilled in the art 
Who have the bene?t of this disclosure Will recogniZe that 
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other baculoviruses and other baculovirus strains may also be 
suitably utiliZed to obtain viral DNA. In particular, it is 
expected that at least the closely related and naturally occur 
ring strains, Trichoplusia ni MNPV, Rachiplusia ou MNPV, 
Galleria mellonella MNPV and any plaque-puri?ed strains 
such as the M3‘ R9, S1 and S3 strains of AcMNPV isolated 
and characteriZed in G. E. Smith and M. D. Summers, J. 
Virol., 33:311-319 (1980), as Well as Bombyx mori NPV 
(BmNPV) may be utiliZed to advantage. Further description 
of those and other strains are found in G. E. Smith and M. D. 
Summers, Virol., 89:517-527 (1978). 
Plasmids for the aforementioned BEVS carrying SEQ ID 
NO: 1 and/or 3, or sequences substantially similar thereto, 
may be designed according to conventional techniques 
knoWn in the art and as described in M. D. Summers and G. E. 
Smith, A Manual of Methods for Baculovirus Vectors and 
Insect Cell Culture Procedures, Texas Agricultural Experi 
ment Station Bulletin No. 1555, Texas A&M University 
(1987) (“Bulletin No. 1555”). (See also V. A. LuckoW and M. 
D. Summers, Virol., 170:31-39 (1989)). In the preferred 
embodiment, the Baculovirus Expression Vector System 
from BD Biosciences Pharmingen is used Which employs a 
modi?ed Aulographa californica nuclear polyhedrosis virus 
(AcNPV) genomeiBD BaculoGoldTM DNA, and an appro 
priate transfer vector. The diversity of AcNPV-based transfer 
vectors, combined With available S. frugzperda Sf9 and Sf21 
cell lines, establish baculovirus expression as a preferred 
system for functional eukaryotic gene expression and the 
large-scale production of recombinant proteins. 
Although the methodology described herein is believed to 
contain su?icient detail to enable one skilled in the art to 
practice the present invention, the plasmids can be con 
structed and puri?ed using standard recombinant DNA tech 
niques described in T. Maniatis, E. F. Fritsch and J. Sam 
brook, Molecular Cloning: A Laboratory Manual, Cold 
Spring Harbor Laboratory (1982) under the current regula 
tions described in United States Dept. of HEW, National 
Institute of Health (NIH) Guidelines for Recombinant DNA 
Research. These references include procedures for the fol 
loWing standard methods: cloning procedures With E. coli 
plasmids, transformation of E. coli cells, plasmid DNA puri 
?cation, phenol extraction of DNA, ethanol precipitation of 
DNA, agarose gel electrophoresis, puri?cation of DNA frag 
ments from agarose gels, and restriction endonuclease and 
other DNA-modifying enZyme reactions. Accordingly, these 
available references are incorporated herein by reference. 
A “reporter nucleic acid sequence” is a DNA molecule that 
expresses a detectable gene product, Which may be reporter 
RNA or reporter protein. The detection may be accomplished 
by any method knoWn to one of skill in the art. For example, 
detection of mRNA expression may be accomplished by 
using Northern blot analysis and detection of protein may be 
accomplished by staining With antibodies speci?c to the pro 
tein, e.g. Western blot analysis. Preferred reporter nucleic 
acid sequences are those that are readily detectable. A 
reporter nucleic acid sequence may be operably linked in a 
DNA construct With a regulatory DNA sequence such that 
detection of the reporter nucleic acid sequence product pro 
vides a measure of the transcriptional activity of the regula 
tory sequence. Examples of reporter nucleic acid sequences 
include, but are not limited to, those coding for alkaline 
phosphatase, chloramphenicol acetyl transferase (CAT), 
luciferase, beta-galactosidase and alkaline phosphatase. 
The terms “transformed” or “transfected” are used inter 
changeably and refer to the process by Which exogenous 
DNA or RNA is transferred or introduced into an appropriate 
host cell.Additionally, nucleic acids encoding other heterolo 
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gous proteins may be introduced into the host cell. Such 
transfected cells include stably transfected cells Wherein the 
inserted DNA is rendered capable of replication in the host 
cell. Typically, stable transfection requires that the exogenous 
DNA be transferred along With a selectable marker nucleic 
acid sequence, such as for example, a nucleic acid sequence 
that confers antibiotic resistance, Which enables the selection 
of the stable transfectants. This marker nucleic acid sequence 
may be ligated to the exogenous DNA or be provided inde 
pendently by simultaneous cotransfection along With the 
exogenous DNA. Transfected cells also include transiently 
expressing cells that are capable of expressing the RNA or 
DNA for limited periods of time. The transfection procedure 
depends on the host cell being transfected. It can include 
packaging the polynucleotide in a virus as Well as direct 
uptake of the polynucleotide. Transformation can result in 
incorporation of the inserted DNA into the genome of the host 
cell or the maintenance of the inserted DNA Within the host 
cell in plasmid form. Methods of transformation/transfection 
are Well knoWn in the art and include, but are not limited to, 
direct injection, such as microinjection, viral infection, par 
ticularly replication-de?cient adenovirus infection, elec 
troporation, lipofection, calcium phosphate-mediated direct 
uptake and the like. 
The term “host cell” generally refers to eukaryotic cells 
and includes any transformable cell Which is capable of 
expressing a P-ank-1 and/or I2-ank-3 proteins and can be, or 
has been, used as a recipient for a vankyrin expression vector. 
Once cells have transiently or stably taken up the vankyrin 
expression vector they are “recombinant” cells. DNA is com 
monly transferred or introduced into recipient mammal cells 
by calcium phosphate-mediated gene transfer, electropora 
tion, lipofection, viral infection and the like. General meth 
ods, vectors and general considerations for gene transfer and 
expression may be found in M. Kriegler, Gene Transfer and 
Expression: A Laboratory Manual, Stockton Press (1990). 
Direct gene transfer to cells in vivo is achieved by the use of 
modi?ed viral vectors, including retroviruses, adenoviruses, 
adeno-associated viruses and herpes viruses, liposomes, and 
direct injection of DNA into certain cell types. See, e.g., 
Wilson, Nature, 365: 691-692 (1993); PlautZ et al, Annals. 
NY Acad. Sci., 716: 144-153 (1994); Farhood et al, Annals 
NYAcad. Sci., 716: 23-34 (1994) and Hyde et al Nature, 362: 
250-255 (1993). 
Recombinant cells provided by this invention expressing 
P-ank-1 and/or I2-ank-3 proteins are intended to produce 
target polypeptides, preferably human proteins and frag 
ments thereof. The process involves culturing the recombi 
nant cells under conditions Wherein the endogenous or heter 
ologous target proteins are expressed, e.g., by inducing the 
activity of a conditional promoter, and purifying the target 
protein from the cell culture. Puri?cation of target proteins is 
Within the skill set or the skilled artisan and generally involves 
the steps of cell lysis, homogeniZation, centrifugation and 
separation of the desired protein by processes such as salt 
fractionation, precipitation, and a variety of chromatographic 
methods such as anion exchange chromatography, hydropho 
bic interaction chromatography, high resolution chromatog 
raphy, gel ?ltration chromatography and the like. 
One aspect of this invention, relates to cells transiently 
expressing a vankyrin expression vector. In one embodiment 
of this aspect of the invention, the transient expression of the 
P-ank-1 and/or I2-ank-3 proteins serves to temporarily 
strengthen the vitality of the culture expressing them. It is 
envisaged that this temporary increase in vitality Will alloW 
for the increased production of target proteins produced by 
and harvested from the host cell line. For example, an estab 
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lished monoclonal antibody (Mab)-producing hybridoma 
cell line may be transiently transfected With the vankyrin 
expression element to obtain an increase in antibody produc 
tion. The most simple method for in vitro production of Mabs 
is standard tissue culture in either large ?asks or roller bottles. 
The production of Mab by hybridomas in tissue culture is 
hybridoma-dependent and can vary betWeen 1-100 ug/ml. 
Therefore, it is often necessity to concentrate Mab from 
supernatant. Transfecting a hybridoma With the vankyrin 
expression element Will alloW for increased Mab production 
and lessen the need for a technician to concentrate antibody in 
the supernatant. 
In another embodiment of this aspect of the invention, the 
cells transiently transfected With a vankyrin expression vector 
are also transiently or permanently co-transfected With an 
additional expression element having a heterologous nucleic 
acid sequence encoding and driving the expression of a het 
erologous target protein. 
Another aspect of the invention relates to cells in Which a 
vankyrin expression element is stably integrated into the 
cells’ genome, thus rendering a recombinant cell line that 
provides superior protein productive capacity When com 
pared to its Wild type cell counterpart. In one embodiment of 
this aspect of the invention, such a cell line is amenable to 
further permanent transfection With an additional expression 
vector carrying a nucleic acid sequence encoding a target 
protein of interest. In another embodiment, such a cell line is 
amenable to transient transfection With an additional expres 
sion vector carrying a nucleic acid sequence encoding a target 
protein of interest. In another embodiment, the target proteins 
produced by and harvested from the cells having permanently 
integrated vankyrin expression vectors may be proteins 
endogenously produced by the host cells themselves. 
Yet a further aspect of the invention relates to a vankyrin 
expression vector that contains additional nucleic acid 
sequences encoding one or more heterologous target proteins 
of interest. Such a vector could be permanently or transiently 
introduced into a host cell line. 
The recombinant cells having the “vankyrin expression 
vector” expressing P-ank-1 and/or I2-ank-3 proteins are 
mammalian, such as, but not limited to Chinese hamster 
ovary (CHO) cells, COS-7 cells, ?broblasts as Well as C127, 
3T3, CHO, HeLa and BHK cell lines. Most preferably, the 
cells are insect cells such as, but not limited to S2 cells, 
Schneider cells, S12 cells, 5B1-4, Tn5, and Sf9 cells. The 
Spodoplera ?’ugiperda Sf9 cell line may be obtained from 
American Type Culture Collection (Rockville, Md.) and is 
assigned accession number ATCC CRL 1711. See M. D. 
Summers and G. E. Smith, Bulletin No. 1555, suora. Those 
skilled in the art Who have the bene?t of this disclosure Will 
recogniZe that other clonal derivatives of the Sf9 cell line as 
Well as T richoplusia ni and other insects such as the silkWorm, 
Bombyx mori, or insect cell cultures derived there from can be 
used to advantage. 
The standard methods of insect cell culture, cotransfection 
and preparation of plasmids in accordance With the examples, 
are set forth in M. D. Summers and G. E. Smith, A Manual of 
Methods for Baculovirus Vectors and Insect Cell Culture 
Procedures, Texas Agricultural Experiment Station Bulletin 
No. 1555, Texas A&M University (1987). This reference also 
pertains to the standard methods of cloning genes into AcM 
NPV transfer vectors, plasmid DNA isolation, transferring 
genes into the AcMNPV genome, viral DNA puri?cation, 
radiolabelling recombinant proteins and preparation of insect 
cell culture media. Accordingly, this available reference is 
incorporated herein by reference. 
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The procedures for the cultivation of viruses and cells are 
described in L. E. Volkman and M. D. Summers, J. Virol, 
19:820-832 (1975) and L. E. Volkman, M. D. Summers and C. 
H. Hsieh, J. V1rol, 19:820-832 (1976). Viral growth kinetics 
Were determined as described by L. E. Volkman, et al., suora, 
using S. ?’ugiperda and a 1.5% agarose overlay. 
Example 1 
For example, When expressed in Sf9 or S1-2 cells, poly 
14 
enhanced protein production in a cell line in Which they are 
expressed, relative to a host cell line transfected in a similar 
manner by a vector lacking such polynucleotides. Speci? 
cally, polynucleotides “substantially similar or identical” to 
SEQ ID NO: 1 and 3, respectively, When expressed in Sf9 or 
S1-2 cells, are capable providing enhanced protein produc 
tion in those cells, relative to Sf9 or S1-2 cells transfected 
With a vector not containing polynucleotides “substantially 
similar or identical” to SEQ ID NO: 1 and 3, respectively. As 
- ~ ~ ~ ~ ~ 10 can be seen in FIG 2 rotein ex ression is extended in Sf9 
nucleot1des “substant1ally s1m1lar or 1dent1cal” to SEQ ID _ _ ' ’p _ p _ 
NO. 1 and 3, respectively’ are Capable improving the 1OngeV_ cells infected W1th recomb1r21ant AcMNPV expressing CsIV 
ity of those cells to such an extent that they resemble non- ahkyhh gehes pfahk'l ahdt_'aht<'3~ Westerh hlets 1h FIG- 2: 
transfected Sf9 or S1-2 cells, Whereas Sf9 or S1-2 cells trans- represeht deteetleh of PretelhS 1h freshly everlayed ehlthr e 
fected With a vector not containing polynucleotides 15 thedle Presehted to cells at each suhseqheht day fellewlhg 
“substantially similar or identical” to SEQ ID NO: 1 and 3, lhfeetleh- The C5IV_Vahkyhh gehes ate lhtraeehhlar pretelhs 
respectively, rapidly lyse about 4 days post infection. FIG. 1. and laehseeretery slghats, thus Pretelh deteeted_1h the medla 
Moreover, the longevity of a cell line expressing polynucle- Overlay 15 the reshlt of that released hy eeh lysls 9r rupture 
otides “substantially similar or identical” to SEQ ID NO: 1 feheWlhg lhfezetleh- Delayed deteetleh of pretelhs trehl 
and 3, respectively, continues to be maintained such that it 20 p'ahk'l ahd I 'ahk'3 Vh'hSeS hhtll day 3 Pest lhfeetleh 15 
resembles non-infected cells at about 6 to about 7 days post reshltaht ef the ehhaheed lehgevlty of Sf9 _eeh5 eeehrhhg 
infection. FIGS. 2, 4 and 5. Therefore, When an Sf9 or S1-2 early duhhg lhfeetleh by these Vh'hSeS (e5 eVldeheed 1h EIG 
cell line is infected With a AcMNPV comprising polynucle- 1)- Addltlehahya heeahse eehs expresslhg Polyhheleetldes 
otides “substantially similar or identical”to SEQ ID NO: 1 or suhstahtlahy s1m1lar er ldehtleat to SEQ ID NO: 1 ahd_ 3: 
3, respectively, the infected Sf9 or S1-2 cell line has enhanced 25 resheetlvelya are able to Predhee PretelhS fer _a lehger Pehed 
longevity relative to an Sf9 or S1-2 cell line infected With a Of thhe, they are able to Produce merepretelh 1h total, thus 
Wild type AcMNPV prov1d1ng an enhanced prote1n product1on capab1l1ty. There 
fore, When an Sf9 or S1-2 cell line is infected With aAcMNPV 
Example 2 comprising polynucleotides “substantially similar or identi 
30 cal” to SEQ ID NO: 1 or 3, respectively, the infected Sf9 or 
Polynucleotides “substantially similar oridentical” to SEQ S1-2 cell line has enhanced protein production relative to an 
ID NO: 1 and 3, respectively, are capable of providing Sf9 or S1-2 cell line infected With a Wild type AcMNPV. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 4 
<21o> SEQ ID No 1 
<211> LENGTH: 513 
<212> TYPE: DNA 
<2l3> ORGANISM: Campoletis sonorensis 
<4oo> SEQUENCE: 1 
atggagattt ctcaaattcg aaagctattc ggtaaaaacc gcgtcacgaa aaataccata 6O 
tttcacgagc ttgcccacgc tggatcattg acactactgt accgggttcg agacaacatt 120 
gacgagccat gcagctctat cctgcaagag gttaatgctg atggagacta tagtatccat 180 
gtggcggcaa agacgcaccg aggacagctt gcagtgagga tcatacaggt gctactagag 240 
ttaggggcaa acctgaatgc gaaagatcgt gtctggaact ttactgtact gcatgtcgca 300 
gttgagcgag acgattacgt cctcgcaaag tggctgcgcc atcacccaca aattgatttg 360 
gatgcaagag gttgggatgg acttacggca catgaaacgt cgttgataac gtgcaacaaa 420 
gagatgatgg atattttccg aaccgacggt gttaacagag ccggtggtac agagccgaaa 480 
gtgaatgaaa gtacatcgaa tgacaatcag cat 513 
<21o> SEQ ID No 2 
<211> LENGTH: 171 
<212> TYPE: PRT 
<2l3> ORGANISM: Campoletis sonorensis 
<400> SEQUENCE: 2 
15 
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Met Glu Ile Ser Gln Ile Arg Lys 
Lys Asn Thr Ile Phe His Glu Leu 
Leu Tyr Arg Val Arg Asp Asn Ile 
35 
Gln Glu Val Asn Ala Asp Gly Asp 
55 
Thr His Arg Gly Gln Leu Ala Val 
Leu Gly Ala Asn Leu Asn Ala Lys 
85 
Leu His Val Ala Val Glu Arg Asp 
100 
Arg His His Pro Gln Ile Asp Leu 
115 120 
Thr Ala His Glu Thr Ser Leu Ile 
130 135 
Ile Phe Arg Thr Asp Gly Val Asn 
145 150 
Val Asn Glu Ser Thr Ser Asn Asp 
165 
<210> SEQ ID NO 3 
<211> LENGTH: 513 
<212> TYPE: DNA 
Leu Phe Gly 
10 
Ala His Ala 
Asp Glu Pro 
Tyr Ser Ile 
Arg Ile Ile 
75 
Asp Arg Val 
Asp Tyr Val 
105 
Asp Ala Arg 
Thr Cys Asn 
Arg Ala Gly 
155 
Asn Gln His 
170 
<2l3> ORGANISM: Campoletis sonorensis 
<400> SEQUENCE: 3 
atggaaaatt ctcaaattgc 
tttcacgagc ttgcccacgc 
caagagccat gcagctctat 
gtggcggcaa aaacgcaccg 
ttgggggcta atctgaatgc 
gttgagcggg aggattacgt 
aatgcgagag gtttcgctgg 
aagatgatgg atattttccg 
gtgaatgaaa gtacatcgaa 
<210> SEQ ID NO 4 
<211> LENGTH: 1'71 
<212> TYPE: PRT 
aaagctgttc 
tggatcgttg 
cctgcaagag 
aggacagctc 
aagagatcgt 
cctcacaatg 
acttacggca 
aaccgacgct 
tgacaatcag 
ggtacaaact 
acacttcttc 
gttaatgcta 
gcagtgagga 
gtctggaact 
tggctgcgcc 
catcaaatgg 
gtatacggag 
cat 
<2l3> ORGANISM: Campoletis sonorensis 
<400> SEQUENCE: 4 
Met Glu Asn Ser Gln Ile Ala Lys 
1 5 
Lys Asn Thr Ile Phe His Glu Leu 
20 
Leu His Arg Val Arg His Asn Ile 
35 
Gln Glu Val Asn Ala Asn Gly Asp 
55 
Leu Phe Gly 
10 
Ala His Ala 
Gln Glu Pro 
Tyr Ser Ile 
Lys Asn Arg Val Thr 
15 
Gly Ser Leu Thr Leu 
30 
Cys Ser Ser Ile Leu 
45 
His Val Ala Ala Lys 
60 
Gln Val Leu Leu Glu 
80 
Trp Asn Phe Thr Val 
95 
Leu Ala Lys Trp Leu 
110 
Gly Trp Asp Gly Leu 
125 
Lys Glu Met Met Asp 
140 
Gly Thr Glu Pro Lys 
160 
gggtcacgaa aaataccata 
accgggttcg acacaacatt 
atggagacta tagtattcat 
tcattcagat actactggaa 
ttactgtact gcatgtcgca 
atcacccaca aatggatttg 
cgttgatgtc gtgcgacaga 
ccggtggttc agagccgaaa 
Thr Asn Trp Val Thr 
15 
Gly Ser Leu Thr Leu 
30 
Cys Ser Ser Ile Leu 
45 
His Val Ala Ala Lys 
60 
60 
120 
180 
240 
300 
360 
420 
480 
513 
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—cont inued 
Thr 
65 
Gln Leu Ala Val Ile His Arg Gly Arg 
Leu Gly Ala Asn Leu Asn Ala Arg Asp Arg Val Trp Asn 
Val Ala Leu His Val Glu Arg Glu Asp Val Leu Thr 
105 
Tyr 
Gln Met Ala Phe 
125 
Leu Asn 
120 
His Pro 
115 
Arg His Asp Arg Gly 
Thr Ala 
130 
Gln Met Ala Leu Met Ser 
135 
His Cys Asp Arg 
140 
Lys 
Ile 
145 
Phe Thr Ala 
150 
Arg Asp Val Tyr Gly Ala Gly Gly 
155 
Ser 
Val Glu Thr 
165 
Asn Ser Ser Asn Asp Asn His 
Ile Gln Ile Leu Leu 
Phe 
Met 
110 
Ala 
Met 
Glu 
Glu 
80 
Thr Val 
Trp Leu 
Gly Leu 
Met Asp 
Pro Lys 
160 
What is claimed is: 
1. A recombinant cell comprising a ?rst isolated nucleic 
acid selected from the group consisting of: 
a. a nucleic acid encoding the polypeptide of SEQ ID NO: 
2; 
b. a nucleic acid that hybridiZes to the nucleic acid of SEQ 
ID NO: 1 under stringent conditions of hybridizing at 
about 68° C. in 5><SSC/5><Denhart’s solution/1.0% SDS, 
and Washing in 0.2><SSC/0.l% SDS at room tempera 
ture, Wherein the nucleic acid encodes a polypeptide 
capable of enhancing longevity and/or protein produc 
tion of a cell line in Which it is expressed; and 
c. a nucleic acid of SEQ ID NO: 1; 
and/ or a second isolated nucleic acid selected from the group 
consisting of: 
a. a nucleic acid encoding the polypeptide of SEQ ID NO: 
4; 
b. a nucleic acid that hybridiZes to the nucleic acid of SEQ 
ID NO: 3 under stringent conditions Wherein the nucleic 
25 
30 
35 
acid encodes a polypeptide capable of enhancing lon 
gevity and/ or protein production of a cell line in Which it 
is expressed; and 
c. A nucleic acid of SEQ ID NO: 3. 
2. The cell of claim 1 Wherein said cell is an Sf9 or an S12 
insect cell. 
3. The cell of claim 1 Wherein said Vector is a baculovirus 
expression vector. 
4. The cell of claim 1 Wherein the ?rst and/ or second 
isolated nucleic acid are stably transfected. 
5. The cell of claim 1 Wherein said cell expresses a target 
protein. 
6. The cell of claim 5, further comprising a heterologous 
isolated nucleotide encoding said target protein. 
7. The cell of claim 5 Wherein said target protein is an 
endogenous protein. 
8. The cell of claim 7, Wherein said cell is a hybridoma and 
said target protein is a monoclonal antibody. 
* * * * * 
